PURPOSE: We hypothesize that measurement of gene expression related to estrogen receptor α (ER; gene name ESR1) within a breast cancer sample represents intrinsic tumoral sensitivity to adjuvant endocrine therapy. METHODS: A genomic index for sensitivity to endocrine therapy (SET) index was defined from genes coexpressed with ESR1 in 437 microarray profiles from newly diagnosed breast cancer, unrelated to treatment or outcome. The association of SET index and ESR1 levels with distant relapse risk was evaluated from microarrays of ER-positive breast cancer in two cohorts who received 5 years of tamoxifen alone as adjuvant endocrine therapy (n = 225 and 298, respectively), a cohort who received neoadjuvant chemotherapy followed by tamoxifen and/or aromatase inhibition (n = 122), and two cohorts who received no adjuvant systemic therapy (n = 208 and 133, respectively). RESULTS: The SET index (165 genes) was significantly associated with distant relapse or death risk in both tamoxifen-treated cohorts (hazard ratio [HR] = 0.70, 95% CI, 0.56 to 0.88, P = .002; and HR = 0.76, 95% CI, 0.63 to 0.93, P = .007) and in the chemo-endocrine-treated cohort (HR = 0.19; 95% CI, 0.05 to 0.69, P = .011) independently from pathologic response to chemotherapy, but was not prognostic in two untreated cohorts. No distant relapse or death was observed after tamoxifen alone if node-negative and high SET or after chemo-endocrine therapy if intermediate or high SET. CONCLUSION: The SET index of ER-related transcription predicted survival benefit from adjuvant endocrine therapy, not inherent prognosis. Prior chemotherapy seemed to enhance the efficacy of adjuvant endocrine therapy related to SET index.
PURPOSE: We hypothesize that measurement of gene expression related to estrogen receptor α (ER; gene name ESR1) within a breast cancer sample represents intrinsic tumoral sensitivity to adjuvant endocrine therapy. METHODS: A genomic index for sensitivity to endocrine therapy (SET) index was defined from genes coexpressed with ESR1 in 437 microarray profiles from newly diagnosed breast cancer, unrelated to treatment or outcome. The association of SET index and ESR1 levels with distant relapse risk was evaluated from microarrays of ER-positive breast cancer in two cohorts who received 5 years of tamoxifen alone as adjuvant endocrine therapy (n = 225 and 298, respectively), a cohort who received neoadjuvant chemotherapy followed by tamoxifen and/or aromatase inhibition (n = 122), and two cohorts who received no adjuvant systemic therapy (n = 208 and 133, respectively). RESULTS: The SET index (165 genes) was significantly associated with distant relapse or death risk in both tamoxifen-treated cohorts (hazard ratio [HR] = 0.70, 95% CI, 0.56 to 0.88, P = .002; and HR = 0.76, 95% CI, 0.63 to 0.93, P = .007) and in the chemo-endocrine-treated cohort (HR = 0.19; 95% CI, 0.05 to 0.69, P = .011) independently from pathologic response to chemotherapy, but was not prognostic in two untreated cohorts. No distant relapse or death was observed after tamoxifen alone if node-negative and high SET or after chemo-endocrine therapy if intermediate or high SET. CONCLUSION: The SET index of ER-related transcription predicted survival benefit from adjuvant endocrine therapy, not inherent prognosis. Prior chemotherapy seemed to enhance the efficacy of adjuvant endocrine therapy related to SET index.
Authors: Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend Journal: Nature Date: 2002-01-31 Impact factor: 49.962
Authors: Natasha Atanaskova; Venkateshwar G Keshamouni; Joseph S Krueger; Janice A Schwartz; Fred Miller; Kaladhar B Reddy Journal: Oncogene Date: 2002-06-06 Impact factor: 9.867
Authors: S Gruvberger; M Ringnér; Y Chen; S Panavally; L H Saal; M Fernö; C Peterson; P S Meltzer Journal: Cancer Res Date: 2001-08-15 Impact factor: 12.701
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Stephen R D Johnston; Julia Head; Sunil Pancholi; Simone Detre; Lesley-Ann Martin; Ian E Smith; Mitch Dowsett Journal: Clin Cancer Res Date: 2003-01 Impact factor: 12.531
Authors: Lajos Pusztai; Mark Ayers; James Stec; Edward Clark; Kenneth Hess; David Stivers; Andrew Damokosh; Nour Sneige; Thomas A Buchholz; Francisco J Esteva; Banu Arun; Massimo Cristofanilli; Daniel Booser; Marguerite Rosales; Vicente Valero; Constantine Adams; Gabriel N Hortobagyi; W Fraser Symmans Journal: Clin Cancer Res Date: 2003-07 Impact factor: 12.531
Authors: Christos Sotiriou; Pratyaksha Wirapati; Sherene Loi; Adrian Harris; Steve Fox; Johanna Smeds; Hans Nordgren; Pierre Farmer; Viviane Praz; Benjamin Haibe-Kains; Christine Desmedt; Denis Larsimont; Fatima Cardoso; Hans Peterse; Dimitry Nuyten; Marc Buyse; Marc J Van de Vijver; Jonas Bergh; Martine Piccart; Mauro Delorenzi Journal: J Natl Cancer Inst Date: 2006-02-15 Impact factor: 13.506
Authors: Rong Hu; Anni Warri; Lu Jin; Alan Zwart; Rebecca B Riggins; Hong-Bin Fang; Robert Clarke Journal: Mol Cell Biol Date: 2014-11-03 Impact factor: 4.272
Authors: H Helen Lin; Yiyin Chung; Chun-Ting Cheng; Ching Ouyang; Yong Fu; Ching-Ying Kuo; Kevin K Chi; Maryam Sadeghi; Peiguo Chu; Hsing-Jien Kung; Chien-Feng Li; Kirsten H Limesand; David K Ann Journal: Autophagy Date: 2018-08-21 Impact factor: 16.016
Authors: Bailiang Li; Yang Li; Xiao-Yu Wang; Zi-Qiao Yan; Huidi Liu; Gui-Rong Liu; Shu-Lin Liu Journal: Am J Cancer Res Date: 2015-01-15 Impact factor: 6.166
Authors: P Sinn; S Aulmann; R Wirtz; S Schott; F Marmé; Z Varga; A Lebeau; H Kreipe; A Schneeweiss Journal: Geburtshilfe Frauenheilkd Date: 2013-09 Impact factor: 2.915